LYCOPENE IN THE MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS
Abstract
Background: Oral Submucous Fibrosis is a potentially malignant disorder well known for its chronic and resistant nature. The conservative drug treatment that is currently available for this disorder is clearly inadequate. The aim of the study was to evaluate the efficacy of oral lycopene therapy when used in combination with conventional intralesional steroid therapy in the management of oral submucous fibrosis.
Methods: Forty five patients with oral submucous fibrosis (grade III and IV) were included under the study and were randomly divided into 3 groups consisting of 15 cases each: Group A (oral lycopene 16 mg/day with biweekly intralesional steroids and hyaluronidase), Group B (oral antioxidant capsules with biweekly intralesional steroids and hyaluronidase) and Group C (biweekly intralesional steroids and hyaluronidase alone). Mouth opening and burning sensation were recorded from baseline to 6 weeks. Cases were followed up to 3 and 6 months.
Results: There was significant increase in mouth opening among all the 3 groups. The results were statistically significant between Group A and C and Group B and C.
Conclusion: Lycopene in combination with intralesional steroids and Hyaluronidase, is highly efficacious in improving the mouth opening and reducing other symptoms in patients with Oral Submucous Fibrosis. No side effects were reported with its usage.Downloads
References
Akbar M. Oral submucous fibrosis – a clinical study. J Indian Dent Acad 1976; 48: 365-73.
Revant H. Chole, Shailesh M. Gondivkar, Amol R. Gadbail, Swati Balsaraf, Sudesh Chaudhary, Snehal V. Dhore et al. Review of drug treatment for oral submucous fibrosis. Oral Oncol 2012; 48: 393–8.
Kumar A, Begawadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 207-13.
Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol 2004; 40: 591-6.
Chandra GDS, Rameshwar DS, Iqbal A. Treatment modalities in Oral submucous fibrosis: how they stand today? Study of 600 cases. Indian Journal of Oral and Maxillofacial surgery 1992; 7: 43-7.
Teodoro AJ, Oliveira FL, Martins NB, Maia GA, Martucci RB, Borojevic R. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int. 2012 Aug 6; 12(1): 36. [Epub ahead of print]
Palozza P, Catalano A, Simone R, Cittadini A. Lycopene as a guardian of redox signalling. Acta Biochim Pol. 2012; 59(1): 21-5.
Stahl W, Junghans A, De Boer B, Driomina ES, Briviba K, Sies H. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. FEBS Lett 1998; 427: 305–8.
Ranganathan K, Devi Mu, Joshua E, Kirankumar K, Saraswathi TR. Oral submucous fibrosis: a case-control study in Chennai, South India. J Oral Pathol Med. 2004; 33(5): 274-7.
Maher R, Lee AJ, Warnakulasuriya KA, Lewis JA, Johnson NW. Role of areca nut in the causation of oral submucous fibrosis: a case-control study in Pakistan. J Oral Pathol Med. 1994; 23(2): 65-9.
Bathi RJ, Parveen S, Burde K. The role of gutka chewing in oral submucous fibrosis: a case-control study. Quintessence Int. 2009; 40(6): e19-25.
Heber D, Lu Q-Y. Overview of mechanisms of action of lycopene. Exp Biol Med 2002; 227: 920-3.
Palozza P, Parrone N, Catalano A, Simone R. Tomato lycopene and inflammatory cascade: basic interactions and clinical implications. Curr Med Chem. 2010; 17(23): 2547-63.
Kitade Y, Watanabe S, Masaki T, Nishioka M, Nishino H. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine, Sho-saiko-to. Hepatol Res. 2002; 22(3): 196-205.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.